Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Secukinumab for psoriatic arthritis:comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Publication Date:
      2018
    • Collection:
      University of Bristol: Bristol Reserach
    • Abstract:
      Aim: A network meta-analysis (NMA) using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (ACR, PASI and PsARC response rates) at 12–16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab, and ustekinumab. Patients & methods: Trials were identified by systematic review. Separate networks were developed for the full study populations, biologic-naïve patients, and biologic-experienced patients. Results: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. Conclusion: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive NMA demonstrated superiority to placebo.
    • File Description:
      application/pdf
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/30230361; info:eu-repo/semantics/altIdentifier/hdl/https://hdl.handle.net/1983/a417a365-2041-41d1-ad33-5fbd8e2ff2af
    • Accession Number:
      10.2217/cer-2018-0075
    • Online Access:
      https://hdl.handle.net/1983/a417a365-2041-41d1-ad33-5fbd8e2ff2af
      https://research-information.bris.ac.uk/en/publications/a417a365-2041-41d1-ad33-5fbd8e2ff2af
      https://doi.org/10.2217/cer-2018-0075
      https://research-information.bris.ac.uk/ws/files/169273458/cer_2018_0075.pdf
    • Rights:
      info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc-nd/4.0/
    • Accession Number:
      edsbas.270E4DAE